Disease · EFO_0004278

sudden cardiac arrest

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sudden cardiac arrest. Diseases, record EFO_0004278. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004278

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sudden cardiac arrest; Open Targets
Open Targets ID: EFO_0004278; Open Targets
Other names: death, sudden, cardiac, sudden cardiac death; Open Targets
MeSH: D016757; MeSH
NCI Thesaurus: C50911; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 6 drugs, from DailyMed; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPINEPHRINE	CHEMBL679	Small molecule	Approval	DailyMed	17	0	0	Drugs and targets
AMIODARONE	CHEMBL633	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OMEGA-3 FATTY ACIDS	CHEMBL4298065		Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
SOTALOL	CHEMBL471	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FISH OIL	CHEMBL3833369		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
MEXILETINE	CHEMBL558	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	2	Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	2	Adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
KCNH2	Voltage-gated inwardly rectifying potassium channel KCNH2	2	HERG blocker	Phase 3	https://conductscience.org/library/genes/3757	Drugs and targets
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
ADRB3	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00729430	Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging	Phase 3	358	2017-06-01	Myocardial Infarction, Death, Sudden, Cardiac	OMEGA-3 FATTY ACIDS	Its record names the disease	ClinicalTrials.gov
NCT02301390	INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events	Not applicable	53	2020-01-27	Ventricular Tachycardia	AMIODARONE	Its record names the disease	ClinicalTrials.gov
NCT05619120	The Effect of Late Na Current Blocker Mexiletine on Giant T-wave Electrical Alternans(STOP-TWA)	Not applicable	50		Giant T-wave Electrical Alternans	MEXILETINE	Its record names the disease	ClinicalTrials.gov
NCT00000531	Antiarrhythmics Versus Implantable Defibrillators (AVID)	Phase 3			Arrhythmia, Cardiovascular Diseases, Death, Sudden, Cardiac, Heart Diseases, Tachycardia, Ventricular, Ventricular Fibrillation	AMIODARONE, SOTALOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
High Dose Omega-3 Fatty Acids Arm vs Placebo Arm: serious adverse events	1 of 180	0 of 178	358	NCT00729430	Trial comparisons
Amiodarone Only vs Amiodarone + Catheter Ablation: Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest	16 of 27	21 of 26	53	NCT02301390	Trial comparisons
Amiodarone Only vs Amiodarone + Catheter Ablation: deaths from any cause	2 of 27	2 of 26	53	NCT02301390	Trial comparisons
Amiodarone Only vs Amiodarone + Catheter Ablation: serious adverse events	11 of 27	8 of 26	53	NCT02301390	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27482002	RESULT	1	PubMed
31948661	DERIVED	1	PubMed
31532795	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004278

GET https://conductscience.org/api/diseases/v1/EFO_0004278/drugs

API reference For AI assistants